Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia

businesswire.com
UTHR United Therapeutics Corporation won a patent litigation case against Liquidia, which is a significant positive development for the company's intellectual property and market position.

United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--( BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District of Delaware issued an opinion that finds Liquidia Technologies, Inc. (Liquidia) infringes two claims of United Therapeutics’ patent covering the use of inhaled treprostinil to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD).

“We are pleased with the Court’s decision, which reinforces our significant research and commitment to bring innovative therapies to the patients we serve. Our immediate priority is ensuring that no patient goes without the therapy they need, and we are ready to support a seamless transition to Tyvaso or Tyvaso DPI should PH-ILD be removed from the Yutrepia label. We look forward to working closely with patients, prescribers, and all other stakeholders throughout this process,” said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics.

The opinion was rendered in litigation concerning United Therapeutics’ U.S. Patent No. 11,826,327 (the ’327 patent), which relates to a method of improving exercise capacity in patients with PH-ILD by inhaling treprostinil at specific dosages. Specifically, the Court determined that Liquidia induces infringement of claims 1 and 14 of the ’327 patent by marketing Yutrepia for PH-ILD. The Court also concluded that Liquidia failed to prove that those claims are invalid.

As a result of the Court’s decision, United Therapeutics believes that it is entitled to an order instructing the U.S. Food and Drug Administration (FDA) to withdraw approval of Liquidia’s new drug application (NDA) for Yutrepia as required by 35 U.S.C. § 271(e)(4)(A). If such an order is granted, it may result in Yutrepia being removed from the U.S. market until such time as FDA can approve labeling omitting the PH-ILD indication. United Therapeutics also intends to seek monetary damages for past infringement, which could include a royalty on past sales of Yutrepia. The Court set a deadline of one week for the parties to submit “an agreed upon form of final judgment” including any such order. If the parties cannot agree on the scope of the final judgment, the Court will need to rule on the issue.

United Therapeutics markets and sells Tyvaso DPI ® (treprostinil) and nebulized Tyvaso ® (treprostinil) Inhalation Solution, both of which are approved for PH-ILD. United Therapeutics has programs available to assist PH-ILD patients in accessing Tyvaso DPI (treprostinil) and nebulized Tyvaso (treprostinil) Inhalation Solution as prescribed by their healthcare provider.

About United Therapeutics

Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build. Visit us at www.unither.com and follow us on LinkedIn, Facebook, and Instagram.

INDICATION

TYVASO (treprostinil) Inhalation Solution and TYVASO DPI (treprostinil) Inhalation Powder are prostacyclin mimetics indicated for the treatment of:

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

DRUG INTERACTIONS/SPECIFIC POPULATIONS

ADVERSE REACTIONS

Please see Full Prescribing Information for TYVASO or TYVASO DPI, Instructions for Use manuals for TD-100 and TD-300 TYVASO ® Inhalation System and TYVASO DPI ®Inhalation Powder, and additional information at www.TYVASOHCP.com or call 1-844-UNITHER (1-844-864-8437).

Forward-Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding: our efforts to bring innovative therapies to the patients we serve; our goal of ensuring that no patient goes without the therapy they need; our readiness to support a seamless transition to Tyvaso or Tyvaso DPI; any remedies and potential outcomes stemming from the Court’s ruling, including the potential withdrawal of FDA’s approval of the Yutrepia NDA, the removal of Yutrepia from the market, the eventual removal of the PH-ILD indication from Yutrepia’s labeling, and the potential award of monetary damages, including a royalty on past sales of Yutrepia; and our goals of expanding the supply of transplantable organs, developing practical technologies that can save lives, creating long-term shareholder value, and operating with sustainable practices. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of September 30, 2026, and assume no obligation to update or revise the information contained in this press release whether because of new information, future events, or any other reason.

TYVASO and TYVASO DPI are registered trademarks of United Therapeutics Corporation.

YUTREPIA is a registered trademark of Liquidia Technologies, Inc.